HCGvsHexarelin

Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.

LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.

HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.

Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as one of the most potent agonists of the growth hormone secretagogue receptor (GHS-R1a). Its strong receptor affinity produces the highest GH release amplitude among the GHRP family, but this potency comes with broader neuroendocrine activation compared to more selective agents like ipamorelin.

At the pituitary level, hexarelin binding to GHS-R1a activates Gq/11-coupled phospholipase C, generating IP3 and DAG. IP3-mediated calcium release from intracellular stores triggers massive GH vesicle exocytosis. The strong GH response also comes with significant stimulation of cortisol (via ACTH release from corticotrophs) and prolactin release from lactotrophs — side effects that limit its clinical utility compared to more selective secretagogues.

Uniquely among GHRPs, hexarelin demonstrates significant cardioprotective properties independent of GH release. GHS-R1a receptors are expressed on cardiomyocytes, and hexarelin binding activates survival signaling through the PI3K/Akt and ERK1/2 pathways, protecting cardiac cells from ischemia-reperfusion injury and apoptosis. Hexarelin also binds to the scavenger receptor CD36 on macrophages and cardiac tissue, which may contribute to its anti-atherosclerotic and cardioprotective effects. Animal studies have demonstrated reduced infarct size and improved cardiac function following hexarelin administration. However, a significant practical limitation is desensitization — continuous hexarelin use leads to progressive reduction in GH response within 2-4 weeks, necessitating cycling protocols to maintain effectiveness.